Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01803867 · ClinicalTrials.gov registry record · Phase 1
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Phase 1 study of Multiple Sclerosis, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 17
- Study locations
NCT01803867: Completed Phase 1 study of Multiple Sclerosis, sponsored by Acorda Therapeutics.
NCT01803867 is a Phase 1 study of Multiple Sclerosis that has completed, run by Acorda Therapeutics. The registered enrollment target is 72 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (88% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01803867, a Phase 1 study of Multiple Sclerosis, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS.
Primary Outcome
Monitoring of adverse events (AEs) will be conducted throughout the study. Adverse events, including serious adverse events will be recorded in the case report forms (CRFs).
Conditions Studied
Interventions
- DRUG rHIgM22
Study Locations (17)
California
- Acorda Investigational Site - Long Beach
- Acorda Investigational Site - Palo Alto
- Acorda Investigational Site - Sacramento
- Acorda Investigational Site - Stanford
Colorado
- Acorda Investigational Site - Aurora
- Acorda Investigational Site - Centennial
Washington
- Acorda Investigational Site - Seattle
- Acorda Investigational Site - Seattle
Indiana
- Acorda Investigational Site - Indianapolis
Kansas
- Acorda Investigational Site - Kansas City
Maryland
- Acorda Investigational Site - Baltimore
Missouri
- Acorda Investigational Site - St Louis
New York
- Acorda Investigational Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
What the finished NCT01803867 record still lists
NCT01803867 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which rHIgM22 is the first listed.
NCT01803867 lists 17 locations in 12 states (California, Colorado, Washington).
Frequently Asked Questions
What is clinical trial NCT01803867 about?
NCT01803867 is a clinical study titled "An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis". This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS.
What is the current status of trial NCT01803867?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2013-03. Estimated completion is 2015-01.
What conditions does trial NCT01803867 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT01803867?
The interventions under investigation include: rHIgM22 (DRUG).
Who is sponsoring clinical trial NCT01803867?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01803867 being conducted?
This trial has 17 study locations across California, Colorado, Indiana, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01803867's enrollment target sits among peer trials
72 152nd of 315 higher than 163 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia